Our Team.

Co-founder and CSO Dr. Ajit Bharti has thirty years of experience in cancer molecular biology. He has developed an IHC test that will predict a cancer patient's response to topo1 inhibitors. He has worked extensively to validate the phosphospecific IHC assay for the last fifteen years and has retrospectively validated the test in CRC and GC patient populations. His expertise in the field is reflected in several peer-reviewed publications

 

Co-founder and CEO Neelabh Bharti has worked in the biotech industry for the last twelve years. He has extensive experience in the biotech business.